Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ROMIPLOSTIM Cause Malignant neoplasm progression? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Malignant neoplasm progression have been filed in association with ROMIPLOSTIM (Nplate). This represents 0.1% of all adverse event reports for ROMIPLOSTIM.

7
Reports of Malignant neoplasm progression with ROMIPLOSTIM
0.1%
of all ROMIPLOSTIM reports
4
Deaths
5
Hospitalizations

How Dangerous Is Malignant neoplasm progression From ROMIPLOSTIM?

Of the 7 reports, 4 (57.1%) resulted in death, 5 (71.4%) required hospitalization, and 2 (28.6%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ROMIPLOSTIM. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does ROMIPLOSTIM Cause?

Off label use (1,027) Platelet count decreased (892) Platelet count abnormal (703) Drug ineffective (513) Thrombocytopenia (369) Headache (359) Death (356) Product storage error (344) Fatigue (251) Circumstance or information capable of leading to medication error (238)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which ROMIPLOSTIM Alternatives Have Lower Malignant neoplasm progression Risk?

ROMIPLOSTIM vs ROMOSOZUMAB ROMIPLOSTIM vs ROMOSOZUMAB-AQQG ROMIPLOSTIM vs ROPEGINTERFERON ALFA-2B-NJFT ROMIPLOSTIM vs ROPINIROLE ROMIPLOSTIM vs ROPIVACAINE

Related Pages

ROMIPLOSTIM Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression ROMIPLOSTIM Demographics